zanidatamab
2 products
4 abstracts
1 target
Target
HER2Abstract
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Seoul National University Hospital, Cancer Research Institute, Seoul, South Korea, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, Quantum Leap Healthcare Collaborative,
Abstract
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).Org: Zymeworks BC, BeiGene Ltd.,
Abstract
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.Org: BeiGene (Shanghai) Co., Ltd., The Fifth Medical Center of Chinese PLA General Hospital,
Product
ZanidatamabProduct
zanidatamab + chemotherapy